Differential cardioprotective properties of the l- and d- enantiomers of bucindolol in a canine model of heart failure.
In previous studies racemic bucindolol was found to reverse the effects of pentobarbital-induced heart failure in anesthetized dogs. Reductions of right ventricular contractile force (RVCF), left ventricular (LV) dp/dt, and aortic blood flow (ABF) serve as indicators of depressed cardiac function in this model. In this study, racemic bucindolol (0.25 mumol/kg +0.25 mumol/kg/hr) again evoked pronounced and sustained stimulant effects on these depressed parameters. l-Bucindolol (0.125 mumol/kg +0.125 mumol/kg/hr) was a more effective stimulator of cardiac function than d-bucindolol in this model. l-Bucindolol elicited maximal increases in RVCF, ABF, LV dp/dt and heart rate of 66, 19, 30 and 11%, respectively. In comparison, d-bucindolol maximally increased these parameters only 20, 14, 12 and 4%, respectively. Total peripheral resistance was reduced 29% by l-bucindolol and 19% by d-bucindolol. The responses to l-bucindolol and racemic bucindolol were essentially the same. The myocardial stimulation and vasodilation profile derived from l-bucindolol (at one-half the molar dose of bucindolol) suggests the possible preference for its use in clinical management of congestive heart failure over bucindolol, the racemic compound. The results further suggest that l-bucindolol could also be used to treat hypertensive patients with depressed cardiac function.